進行再発卵巣がんの世界市場レポート 2025年

進行再発卵巣がん市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.4%で37億5,000万米ドルに成長します。予測期間中に成長が見込まれる背景には、個別化医療への注目の高まり、標的療法や免疫療法の拡大、がん研究への投資の増加、新興市場におけるヘルスケアアクセスの改善、高齢化などがあります。主な動向としては、早期発見のための人工知能の利用、リキッドバイオプシー技術の開発、バイオマーカー主導型治療の統合、遺伝子編集技術の進歩、精密医療の採用拡大などが挙げられます。

個別化医療の重視の高まりは、進行再発卵巣がん市場の成長を促進すると予想されます。個別化医療は、最も効果的で的を絞った治療を提供するために、個人の遺伝子プロファイル、ライフスタイル、特定の健康状態に合わせて治療を調整することを含みます。個別化医療の台頭は、ゲノミクス、バイオテクノロジー、データ分析の進歩により、遺伝子変異や疾患バイオマーカーをより正確に特定できるようになったことが背景にあります。進行再発卵巣がんは、各患者の特定の遺伝子変異や腫瘍の分子的特徴に対処するカスタマイズされた治療アプローチの必要性を強調することで、個別化医療の発展に貢献し、それによって治療成績を向上させ、再発率を低下させる。例えば、2024年2月、個別化医療の導入を提唱する米国の組織である個別化医療連合（Personalized Medicine Coalition）は、米国食品医薬品局が希少疾病患者向けに16の新たな個別化治療を承認したと報告し、これは2022年の6から増加しました。その結果、個別化医療への注目の高まりが進行再発卵巣がん市場の拡大に拍車をかけています。

進行再発卵巣がん市場の主要企業は、治療精度の向上、がん細胞への薬物送達の改善、オフターゲット効果の低減、従来の治療法に対する耐性への対応などを目的として、抗体薬物複合体のような革新的治療の開発を優先しています。抗体薬物複合体（ADC）は、がん細胞に特異的なモノクローナル抗体と細胞傷害性薬剤を組み合わせた標的がん治療の一形態であり、腫瘍細胞への正確な薬物送達を確保すると同時に、健康な組織への害を最小限に抑えます。例えば、2024年1月、中国を拠点とする生物製剤会社RemeGen Co.Ltd.は、独自に開発したメソセリン（MSLN）標的抗体薬物複合体RC88が、プラチナ製剤抵抗性の再発上皮性卵巣がん、卵管がん、原発性腹膜がんの治療薬としてFDAのファスト・トラック指定を受けたと発表しました。この製品は、組み換えヒト化抗MSLNモノクローナル抗体と、強力な微小管阻害剤であるモノメチルアウリスタチンE（MMAE）を統合したものです。ADC技術は、腫瘍細胞への細胞毒性薬剤の正確な送達を容易にし、全身毒性を最小限に抑えながら治療効果を高める。RemeGen社は、抗体と薬剤の結合を最適化する独自のブリッジング技術を利用しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界進行再発卵巣がんPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の進行再発卵巣がん市場：成長率分析
• 世界の進行再発卵巣がん市場の実績：規模と成長, 2019-2024
• 世界の進行再発卵巣がん市場の予測：規模と成長, 2024-2029, 2034F
• 世界進行再発卵巣がん総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の進行再発卵巣がん市場：疾患タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 上皮性卵巣がん
• 非上皮性卵巣がん
• 世界の進行再発卵巣がん市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 標的療法
• 化学療法
• 手術
• 放射線
• 生物学的療法
• 世界の進行再発卵巣がん市場患者の年齢層別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 中年（40～59歳）
• 小児科
• シニア（60歳以上）
• 若年成人（18～39歳）
• 世界の進行再発卵巣がん市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 薬局
• 世界の進行再発卵巣がん市場上皮性卵巣がんの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 漿液性がん
• 類内膜がん
• 明細胞がん
• 粘液がん
• 世界の進行再発卵巣がん市場非上皮性卵巣がんの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 胚細胞腫瘍
• 性索間質性腫瘍
• 転移性腫瘍

第7章 地域別・国別分析

• 世界の進行再発卵巣がん市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の進行再発卵巣がん市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 進行再発卵巣がん市場：競合情勢
• 進行再発卵巣がん市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bristol Myers Squibb Company
• AstraZeneca plc
• Novartis International AG
• GSK plc
• Eli Lilly and Company
• Amgen Inc.
• Regeneron Pharmaceuticals Inc.
• Genentech Inc.
• Exelixis Inc.
• Mirati Therapeutics Inc.
• Kite Pharma Inc.
• ImmunoGen Inc.
• Clovis Oncology Inc.
• Debiopharm International SA
• Celsion Corporation

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 進行再発卵巣がん市場2029：新たな機会を提供する国
• 進行再発卵巣がん市場2029：新たな機会を提供するセグメント
• 進行再発卵巣がん市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Advanced recurrent ovarian cancer is a form of ovarian cancer that has returned after initial treatment and has progressed beyond the ovaries. This condition is typically classified as stage III or IV, where the cancer may spread to nearby organs in the pelvis or abdomen and potentially metastasize to distant sites, such as the lungs.

The primary types of advanced recurrent ovarian cancer include epithelial ovarian cancer and non-epithelial ovarian cancer. Epithelial ovarian cancer originates in the epithelial cells lining the ovaries, which are responsible for producing eggs and hormones. Treatment options include targeted therapy, chemotherapy, surgery, radiation, and biological therapy. Patients fall into different age groups, including pediatric, young adults (18-39), middle-aged (40-59), and seniors (60+). These treatments are administered in various healthcare settings, such as hospitals, clinics, and pharmacies.

The advanced recurrent ovarian cancer market research report is one of a series of new reports from The Business Research Company that provides advanced recurrent ovarian cancer market statistics, including advanced recurrent ovarian cancer industry global market size, regional shares, competitors with an advanced recurrent ovarian cancer market share, detailed advanced recurrent ovarian cancer market segments, market trends and opportunities, and any further data you may need to thrive in the advanced recurrent ovarian cancer industry. This advanced recurrent ovarian cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The advanced recurrent ovarian cancer market size has grown strongly in recent years. It will grow from $2.50 billion in 2024 to $2.72 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth during the historic period was driven by the increasing prevalence of ovarian cancer, limited treatment options for advanced stages, rising awareness of ovarian cancer symptoms, growing healthcare spending, and advancements in chemotherapy regimens.

The advanced recurrent ovarian cancer market size is expected to see strong growth in the next few years. It will grow to $3.75 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The projected growth during the forecast period is driven by an increasing focus on personalized medicine, the expansion of targeted therapies and immunotherapies, rising investment in cancer research, improved healthcare access in emerging markets, and an aging population. Key trends include the use of artificial intelligence for early detection, the development of liquid biopsy technologies, the integration of biomarker-driven therapies, advancements in gene editing technologies, and the growing adoption of precision medicine.

The increasing emphasis on personalized medicine is expected to drive the growth of the advanced recurrent ovarian cancer market. Personalized medicine involves tailoring medical treatment to an individual's genetic profile, lifestyle, and specific health conditions to provide the most effective and targeted therapy. The rise of personalized medicine is fueled by advancements in genomics, biotechnology, and data analytics, allowing for more precise identification of genetic variations and disease biomarkers. Advanced recurrent ovarian cancer contributes to the development of personalized medicine by emphasizing the need for customized treatment approaches that address specific genetic mutations and molecular characteristics of each patient's tumor, thereby improving therapeutic outcomes and reducing recurrence rates. For example, in February 2024, the Personalized Medicine Coalition, a US-based organization advocating for personalized medicine adoption, reported that the U.S. Food and Drug Administration approved 16 new personalized treatments for rare disease patients, an increase from six in 2022. As a result, the growing focus on personalized medicine is fueling the expansion of the advanced recurrent ovarian cancer market.

Leading companies in the advanced recurrent ovarian cancer market are prioritizing the development of innovative treatments, such as antibody-drug conjugates, to enhance treatment precision, improve drug delivery to cancer cells, reduce off-target effects, and address resistance to traditional therapies. Antibody-drug conjugates (ADCs) are a form of targeted cancer therapy that combines a monoclonal antibody specific to cancer cells with a cytotoxic drug, ensuring precise drug delivery to tumor cells while minimizing harm to healthy tissues. For instance, in January 2024, RemeGen Co. Ltd., a China-based biopharmaceutical company, announced that its independently developed RC88, a mesothelin (MSLN)-targeting antibody-drug conjugate, received FDA Fast Track Designation for treating platinum-resistant recurrent epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancers. This product integrates a recombinant humanized anti-MSLN monoclonal antibody with monomethyl auristatin E (MMAE), a potent microtubule inhibitor. The ADC technology facilitates the precise delivery of cytotoxic agents to tumor cells, enhancing therapeutic efficacy while minimizing systemic toxicity. RemeGen utilizes a proprietary bridging technology to optimize the connection between antibodies and drugs.

In February 2024, AbbVie Inc., a US-based pharmaceutical company, acquired ImmunoGen Inc. for an undisclosed amount. This acquisition aims to strengthen AbbVie's oncology portfolio by incorporating ImmunoGen's expertise in antibody-drug conjugates (ADCs) and its promising treatments for advanced cancers, including ovarian cancer. ImmunoGen Inc. is a US-based company specializing in the development of ADC therapies for cancer treatment.

Major players in the advanced recurrent ovarian cancer market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca plc, Novartis International AG, GSK plc, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Genentech Inc., Exelixis Inc., Mirati Therapeutics Inc., Kite Pharma Inc., ImmunoGen Inc., Clovis Oncology Inc., Debiopharm International SA, Celsion Corporation.

North America was the largest region in the advanced recurrent ovarian cancer market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in advanced recurrent ovarian cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the advanced recurrent ovarian cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The advanced recurrent ovarian cancer market includes revenues earned by entities by providing services such as diagnostic services, treatment services, and supportive care services, and related products such as pharmaceutical drugs, diagnostic products, medical devices, and supportive care products. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Advanced Recurrent Ovarian Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on advanced recurrent ovarian cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for advanced recurrent ovarian cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The advanced recurrent ovarian cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disease Type: Epithelial Ovarian Cancer, Non-Epithelial Ovarian Cancer
• 2) By Treatment Type: Targeted Therapy, Chemo Therapy, Surgery, Radiation, Biological Therapy
• 3) By Patient Age Group: Middle Aged (40-59), Pediatric, Senior (60+), Young Adult (18-39)
• 4) By End User: Hospitals, Clinics, Pharmacies
• Subsegments:
• 1) By Epithelial Ovarian Cancer: Serous Carcinoma; Endometrioid Carcinoma; Clear Cell Carcinoma; Mucinous Carcinoma
• 2) By Non-Epithelial Ovarian Cancer: Germ Cell Tumors; Sex Cord-Stromal Tumors; Metastatic Tumors
• Companies Mentioned: Pfizer Inc.; Roche Holding AG; Merck & Co. Inc.; AbbVie Inc.; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Advanced Recurrent Ovarian Cancer Market Characteristics

3. Advanced Recurrent Ovarian Cancer Market Trends And Strategies

4. Advanced Recurrent Ovarian Cancer Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Advanced Recurrent Ovarian Cancer Growth Analysis And Strategic Analysis Framework

• 5.1. Global Advanced Recurrent Ovarian Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Advanced Recurrent Ovarian Cancer Market Growth Rate Analysis
• 5.4. Global Advanced Recurrent Ovarian Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Advanced Recurrent Ovarian Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Advanced Recurrent Ovarian Cancer Total Addressable Market (TAM)

6. Advanced Recurrent Ovarian Cancer Market Segmentation

• 6.1. Global Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Epithelial Ovarian Cancer
• Non-Epithelial Ovarian Cancer
• 6.2. Global Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Targeted Therapy
• Chemo Therapy
• Surgery
• Radiation
• Biological Therapy
• 6.3. Global Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Middle Aged (40-59)
• Pediatric
• Senior (60+)
• Young Adult (18-39)
• 6.4. Global Advanced Recurrent Ovarian Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Pharmacies
• 6.5. Global Advanced Recurrent Ovarian Cancer Market, Sub-Segmentation Of Epithelial Ovarian Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Serous Carcinoma
• Endometrioid Carcinoma
• Clear Cell Carcinoma
• Mucinous Carcinoma
• 6.6. Global Advanced Recurrent Ovarian Cancer Market, Sub-Segmentation Of Non-Epithelial Ovarian Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Germ Cell Tumors
• Sex Cord-Stromal Tumors
• Metastatic Tumors

7. Advanced Recurrent Ovarian Cancer Market Regional And Country Analysis

• 7.1. Global Advanced Recurrent Ovarian Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Advanced Recurrent Ovarian Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Advanced Recurrent Ovarian Cancer Market

• 8.1. Asia-Pacific Advanced Recurrent Ovarian Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Advanced Recurrent Ovarian Cancer Market

• 9.1. China Advanced Recurrent Ovarian Cancer Market Overview
• 9.2. China Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Advanced Recurrent Ovarian Cancer Market

• 10.1. India Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Advanced Recurrent Ovarian Cancer Market

• 11.1. Japan Advanced Recurrent Ovarian Cancer Market Overview
• 11.2. Japan Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Advanced Recurrent Ovarian Cancer Market

• 12.1. Australia Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Advanced Recurrent Ovarian Cancer Market

• 13.1. Indonesia Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Advanced Recurrent Ovarian Cancer Market

• 14.1. South Korea Advanced Recurrent Ovarian Cancer Market Overview
• 14.2. South Korea Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Advanced Recurrent Ovarian Cancer Market

• 15.1. Western Europe Advanced Recurrent Ovarian Cancer Market Overview
• 15.2. Western Europe Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Advanced Recurrent Ovarian Cancer Market

• 16.1. UK Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Advanced Recurrent Ovarian Cancer Market

• 17.1. Germany Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Advanced Recurrent Ovarian Cancer Market

• 18.1. France Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Advanced Recurrent Ovarian Cancer Market

• 19.1. Italy Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Advanced Recurrent Ovarian Cancer Market

• 20.1. Spain Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Advanced Recurrent Ovarian Cancer Market

• 21.1. Eastern Europe Advanced Recurrent Ovarian Cancer Market Overview
• 21.2. Eastern Europe Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Advanced Recurrent Ovarian Cancer Market

• 22.1. Russia Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Advanced Recurrent Ovarian Cancer Market

• 23.1. North America Advanced Recurrent Ovarian Cancer Market Overview
• 23.2. North America Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Advanced Recurrent Ovarian Cancer Market

• 24.1. USA Advanced Recurrent Ovarian Cancer Market Overview
• 24.2. USA Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Advanced Recurrent Ovarian Cancer Market

• 25.1. Canada Advanced Recurrent Ovarian Cancer Market Overview
• 25.2. Canada Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Advanced Recurrent Ovarian Cancer Market

• 26.1. South America Advanced Recurrent Ovarian Cancer Market Overview
• 26.2. South America Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Advanced Recurrent Ovarian Cancer Market

• 27.1. Brazil Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Advanced Recurrent Ovarian Cancer Market

• 28.1. Middle East Advanced Recurrent Ovarian Cancer Market Overview
• 28.2. Middle East Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Advanced Recurrent Ovarian Cancer Market

• 29.1. Africa Advanced Recurrent Ovarian Cancer Market Overview
• 29.2. Africa Advanced Recurrent Ovarian Cancer Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Advanced Recurrent Ovarian Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Advanced Recurrent Ovarian Cancer Market, Segmentation By Patient Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Advanced Recurrent Ovarian Cancer Market Competitive Landscape And Company Profiles

• 30.1. Advanced Recurrent Ovarian Cancer Market Competitive Landscape
• 30.2. Advanced Recurrent Ovarian Cancer Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Advanced Recurrent Ovarian Cancer Market Other Major And Innovative Companies

• 31.1. Bristol Myers Squibb Company
• 31.2. AstraZeneca plc
• 31.3. Novartis International AG
• 31.4. GSK plc
• 31.5. Eli Lilly and Company
• 31.6. Amgen Inc.
• 31.7. Regeneron Pharmaceuticals Inc.
• 31.8. Genentech Inc.
• 31.9. Exelixis Inc.
• 31.10. Mirati Therapeutics Inc.
• 31.11. Kite Pharma Inc.
• 31.12. ImmunoGen Inc.
• 31.13. Clovis Oncology Inc.
• 31.14. Debiopharm International SA
• 31.15. Celsion Corporation

32. Global Advanced Recurrent Ovarian Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Advanced Recurrent Ovarian Cancer Market

34. Recent Developments In The Advanced Recurrent Ovarian Cancer Market

35. Advanced Recurrent Ovarian Cancer Market High Potential Countries, Segments and Strategies

• 35.1 Advanced Recurrent Ovarian Cancer Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Advanced Recurrent Ovarian Cancer Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Advanced Recurrent Ovarian Cancer Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer